CoChat
Sign Up
Cited by 30RNA Interference and Gene DeliveryGlioma Diagnosis and TreatmentNanoparticle-Based Drug Delivery

Intracranial delivery of synthetic mRNA to suppress glioblastoma

Open access
Peng, Hao, Guo, Xingrong, He, Jinjuan, Duan, Chao, Yang, Minghuan, Zhang, Xianghua, Zhang, Li, Fu, Rui +8 more·2022·Molecular Therapy - Oncolytics
DOI 10.1016/j.omto.2021.12.010PMC PMC8724946
Open this paper in CoChat — free accountOpen PDF

Abstract

Owing to messenger RNA's unique biological advantages, it has received increasing attention to be used as a therapeutic, known as mRNA-based gene therapy. It is critical to have an ideal strategy of mRNA gene therapy for glioma, which grows in a special environment. In the present study, we screened out a safe and efficient transfection reagent for intracranial delivery of synthetic mRNA in mouse brain. First, in order to analyze the effect of different transfection reagents on the intracranial delivery of mRNA, the synthetic luciferase mRNA was wrapped with two different transfection reagents and microinjected into the brain at the fixed point. The expression status of delivered mRNA was monitored by a small animal imaging system. The possible reagent-induced biological toxicity was evaluated by behavioral and blood biochemical measurements. Then, to test the therapeutic effect of our intracranial delivery mRNA model on glioma, synthetic modified tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mRNA was used as an example of therapeutic application. This model demonstrated that synthetic mRNA could be successfully delivered into the brain using commercially available transfection reagents, and TransIT-mRNA showed better results than in vivo -jetPEI kit. This model can be applied in precise targeting and personalized gene therapy of glioma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omto.2021.12.010

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • An intracerebral injection avoids the tissue barrier that the blood-CSF barrier or blood-brain-barrier represents and consequently should lead to significantly higher brain transfection levels by specifically targeting local regions of the brain.

    “An intracerebral injection avoids the tissue barrier that blood-cerebrospinal fluid (CSF) barrier or blood-brain-barrier (BBB) represents, and consequently should lead to significantly higher brain transfection levels by specifically targeting local regions of the brain (4, 20, 22, 26, 27).”

    From Lipid Nanoparticles Deliver mRNA to the Brain after an Intracerebral Injection (2023) · cites this paper as [4]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

  • Intracerebral injections are clinically feasible and are performed in a variety of clinical scenarios and preclinical settings.

    “Intracerebral injections are clinically feasible, and are performed in a variety of clinical scenarios (17–23), as well as in various preclinical settings (4, 24–27).”

    From Lipid Nanoparticles Deliver mRNA to the Brain after an Intracerebral Injection (2023) · cites this paper as [4]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 31

  1. [1]Sanders N. Rudolph C. Braeckmans K. De Smedt S.C. Demeester J. Extracellular barriers in respiratory gene therapy Adv. Drug Deliv. Rev. 61 2009 115 127 19146894 PMC7103358
  2. [2]Rittig S.M. Haentschel M. Weimer K.J. Heine A. Muller M.R. Brugger W. Horger M.S. Maksimovic O. Stenzl A. Hoerr I. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients Mol. Ther.: J. Am. Soc. Gene Ther. 19 2011 990 999 PMC3098631 21189474
  3. [3]Wang Y. Su H.H. Yang Y. Hu Y. Zhang L. Blancafort P. Huang L. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy Mol. Ther.: J. Am. Soc. Gene Ther. 21 2013 358 367 PMC3594035 23229091
  4. [4]Wang F. Kream R.M. Stefano G.B. An evidence based perspective on mRNA-SARS-CoV-2 vaccine development Med. Sci. monitor: Int. Med. J. Exp. Clin. Res. 26 2020 e924700 PMC7218962 32366816
  5. [5]Vabret N. Preclinical data from SARS-CoV-2 mRNA vaccine Nat. Rev. Immunol. 20 2020 461 PMC7306651 32572246
  6. [7]Diken M. Kreiter S. Selmi A. Türeci O. Sahin U. Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies Methods Mol. Biol. (Clifton, NJ) 969 2013 235 246 23296938
  7. [8]Thomsen L.B. Larsen A.B. Lichota J. Moos T. Nanoparticle-derived non-viral genetic transfection at the blood-brain barrier to enable neuronal growth factor delivery by secretion from brain endothelium Curr. Med. Chem. 18 2011 3330 3334 21728969
  8. [10]Belkahla H. Herlem G. Picaud F. Gharbi T. Hémadi M. Ammar S. Micheau O. TRAIL-NP hybrids for cancer therapy: a review Nanoscale 9 2017 5755 5768 28443893
  9. [11]Dianat-Moghadam H. Heidarifard M. Mahari A. Shahgolzari M. Keshavarz M. Nouri M. Amoozgar Z. TRAIL in oncology: from recombinant TRAIL to nano- and self-targeted TRAIL-based therapies Pharmacol. Res. 2020 104716 32084560
  10. [12]Karikó K. Muramatsu H. Keller J.M. Weissman D. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin Mol. Ther.: J. Am. Soc. Gene Ther. 20 2012 948 953 PMC3345990 22334017
  11. [14]Jiang Y. Gaudin A. Zhang J. Agarwal T. Song E. Kauffman A.C. Tietjen G.T. Wang Y. Jiang Z. Cheng C.J. A "top-down" approach to actuate poly(amine-co-ester) terpolymers for potent and safe mRNA delivery Biomaterials 176 2018 122 130 29879653 PMC6038928
  12. [15]Stadler C.R. Bähr-Mahmud H. Celik L. Hebich B. Roth A.S. Roth R.P. Karikó K. Türeci Ö. Sahin U. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies Nat. Med. 23 2017 815 817 28604701
  13. [16]Wu L. Zhou W. Lin L. Chen A. Feng J. Qu X. Zhang H. Yue J. Delivery of therapeutic oligonucleotides in nanoscale Bioact Mater. 7 2022 292 323 34466734 PMC8379367
  14. [17]Han H.R. Park S.A. Ahn S. Jeun S.S. Ryu C.H. Evaluation of combination treatment effect with TRAIL-secreting mesenchymal stem cells and compound C against glioblastoma Anticancer Res. 39 2019 6635 6643 31810928
  15. [18]Gamie Z. Kapriniotis K. Papanikolaou D. Haagensen E. Da Conceicao Ribeiro R. Dalgarno K. Krippner-Heidenreich A. Gerrand C. Tsiridis E. Rankin K.S. TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: pre-clinical and clinical data Cancer Lett. 409 2017 66 80 28888998
  16. [19]Mert U. Sanlioglu A.D. Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer Cell Mol. Life Sci. 74 2017 245 255 27510421 PMC11107773
  17. [20]Duiker E.W. Mom C.H. de Jong S. Willemse P.H. Gietema J.A. van der Zee A.G. de Vries E.G. The clinical trail of TRAIL Eur. J. Cancer 42 2006 2233 2240 16884904
  18. [21]Legler K. Hauser C. Egberts J.H. Willms A. Heneweer C. Boretius S. Röcken C. Glüer C.C. Becker T. Kluge M. The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells Cell Death Dis. 9 2018 445 29670075 PMC5906476
  19. [22]Stuckey D.W. Shah K. TRAIL on trial: preclinical advances in cancer therapy Trends Mol. Med. 19 2013 685 694 24076237 PMC3880796
  20. [23]Tisato V. Gonelli A. Voltan R. Secchiero P. Zauli G. Clinical perspectives of TRAIL: insights into central nervous system disorders Cell Mol. Life Sci. 73 2016 2017 2027 26910728 PMC4834097
  21. [24]Wu G.S. TRAIL as a target in anti-cancer therapy Cancer Lett. 285 2009 1 5 19299078
  22. [25]Zhu Z.C. Liu J.W. Yang C. Li M.J. Wu R.J. Xiong Z.Q. Targeting KPNB1 overcomes TRAIL resistance by regulating DR5, Mcl-1 and FLIP in glioblastoma cells Cell Death Dis. 10 2019 118 30742128 PMC6370806
  23. [26]Chyuan I.T. Tsai H.F. Wu C.S. Hsu P.N. TRAIL suppresses gut inflammation and inhibits colitogeic T-cell activation in experimental colitis via an apoptosis-independent pathway Mucosal Immunol. 12 2019 980 989 31076664 PMC7746525
  24. [27]Mert U. Adawy A. Scharff E. Teichmann P. Willms A. Haselmann V. Colmorgen C. Lemke J. von Karstedt S. Fritsch J. TRAIL induces nuclear translocation and chromatin localization of TRAIL death receptors Cancers (Basel). 11 2019 1167 PMC6721811 31416165
  25. [28]Hope J.M. Lopez-Cavestany M. Wang W. Reinhart-King C.A. King M.R. Activation of Piezo1 sensitizes cells to TRAIL-mediated apoptosis through mitochondrial outer membrane permeability Cell Death Dis. 10 2019 837 31685811 PMC6828775
  26. [29]Kretz A.L. Trauzold A. Hillenbrand A. Knippschild U. Henne-Bruns D. von Karstedt S. Lemke J. TRAILblazing strategies for cancer treatment Cancers (Basel). 11 2019 456 PMC6521007 30935038
  27. [30]Zhu Q. Man S.M. Karki R. Malireddi R.K.S. Kanneganti T.D. Detrimental type I Interferon signaling dominates protective AIM2 inflammasome responses during Francisella novicida infection Cell Rep. 22 2018 3168 3174 29562174 PMC6204211
  28. [31]Gillissen B. Wendt J. Richter A. Richter A. Müer A. Overkamp T. Gebhardt N. Preissner R. Belka C. Dörken B. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma J. Cell Biol. 188 2010 851 862 20308427 PMC2845080
  29. [32]Guo X.R. Yang Z.S. Tang X.J. Zou D.D. Gui H. Wang X.L. Ma S.N. Yuan Y.H. Fang J. Wang B. The application of mRNA-based gene transfer in mesenchymal stem cell-mediated cytotoxicity of glioma cells Oncotarget 7 2016 55529 55542 27487125 PMC5342434
  30. [33]Chen Q. Wu J. Ye Q. Ma F. Zhu Q. Wu Y. Shan C. Xie X. Li D. Xiaoyan Zhan X. Treatment of human glioblastoma with a live attenuated Zika virus vaccine candidate mBio. 9 2018 e01683-18 PMC6143740 30228241
  31. [34]Xiong L. Zhou H. Zhao Q. Xue L. Al-Hawwas M. He J. Wu M. Zou Y. Yang M. Dai J. Overexpression of miR-124 protects against neurological dysfunction induced by neonatal hypoxic-ischemic brain injury Cell Mol. Neurobiol. 40 2020 737 750 31916069 PMC11448850

Cited by

Sorted by citations

Authors
Peng, H., Guo, X., He, J., Duan, C., Yang, M., Zhang, X., Zhang, L., Fu, R., Wang, B., Wang, D., Chen, H., Xie, M., Feng, P., Dai, L., Tang, X., & Luo, J.
Affiliations
Hubei University of Medicine (CN)
Corresponding author
  • Tang, Xiangjun
  • Luo, Jie
ORCID
Venue
Molecular Therapy - Oncolytics
Publisher
Elsevier BV
Published
2022-03
Volume
24
Pages
160-170
ISSN
2372-7705 (ISSN-L)
DOI
10.1016/j.omto.2021.12.010
PMC
PMC8724946
OpenAlex
W4200040305
Cited by
30
References
3
Citations by year
2026: 3 · 2025: 9 · 2024: 3 · 2023: 12 · 2022: 3
FWCI
1.41
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Therapy — Oncolytics (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
glioblastoma, transfection reagents, transfection toxicity, personalized gene therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review